RxDoctor Payments Data

Sravani Mehta, MD

Physical Medicine & Rehabilitation · Franklin, TNNPI 1902127582

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Piramal Critical Care at 35.2% of the total. Reporting peaked in 2020 at $116 and has fallen 79.7% since, to $24 in 2025.

$499in general payments, 2019–2025

Across 25 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Piramal Critical Care$176
  • Vanda Pharmaceuticals Inc.$156
  • Organogenesis Inc.$79
  • Otsuka America Pharmaceutical, Inc.$73
  • Pfizer$16

What the payments were for

  • Food & beverage$499100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Piramal Critical Care9$176
Vanda Pharmaceuticals Inc.9$156
Organogenesis Inc.3$79
Otsuka America Pharmaceutical, Inc.3$73
Pfizer1$16

How this compares

$499 in reported general payments places this provider in the 65th percentile of 134 physical medicine & rehabilitation providers in Tennessee.

See all physical medicine & rehabilitation providers in Tennessee

Medicare billing

Part B allowed, 2024
$214,786
Medicare patients
542
Services billed
5,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin92$117,497
EliquisApixaban270$69,941
XareltoRivaroxaban190$44,751
MyrbetriqMirabegron155$34,824
JardianceEmpagliflozin107$25,375
JanuviaSitagliptin Phosphate121$23,169
GemtesaVibegron112$19,617
NuedextaDextromethorphan Hbr/Quinidine46$18,210
Divalproex Sodium194$16,014
OzempicSemaglutide12$12,347
TrulicityDulaglutide29$11,672
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$10,878
Breo ElliptaFluticasone/Vilanterol24$9,526
EntrestoSacubitril/Valsartan51$9,341
Potassium Chloride270$8,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$69,941270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 134 physical medicine & rehabilitation providers in Tennessee.

Other physical medicine & rehabilitation in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →